ConferencesGlioblastoma ("GBM")Medulloblastoma

VBI Vaccines to Present at the Society of Neuro-Oncology Annual Meeting

By November 10, 2016No Comments

VBI Vaccines Inc. (Nasdaq: VBIV) (TSX: VBV) (“VBI”) is scheduled to present at the Society of Neuro-Oncology Annual Meeting on Friday, November 18, 2016 at 7:00 PM MST (5:00 PM EST). The event is being held at the Scottsdale Fairmont Princess Hotel in Scottsdale, AZ.

During the poster presentation, CMV gB/pp65 eVLPs Formulated with GM-CSF as a Therapeutic Vaccine Against Glioblastoma and Medulloblastoma, Dr. David E. Anderson, Ph.D., VBI’s Chief Scientific Officer, will summarize the use of VBI’s eVLP Platform in development of VBI-1901, VBI’s therapeutic vaccine candidate for adult glioblastoma multiform (“GBM”) and pediatric medulloblastoma. VBI anticipates filing an Investigational New Drug (“IND”) application with the U.S. FDA in the first half of 2017 to initiate a Phase I/IIa clinical trial in patients with GBM. The FDA will consider a Fast Track designation for VBI-1901 at the time of the IND submission.

“Failures of many past therapeutic cancer vaccines can be attributed to several common shortcomings, including the inherently poor immunogenicity of the tumor antigens used, the failure to induce a broadly reactive immune response, and the failure to sustain an immune response,” said Dr. Anderson. “VBI-1901 was designed to address these shortcomings, and we believe this will differentiate it and increase its potential for clinical success.”

Now in its 21st year, the Society of Neuro-Oncology Annual Meeting annual meeting promotes advancements in the field of neuro-oncology through research and education. For more information, visit:

Event Details

  • Event: 21st Annual Society of Neuro-Oncology Annual Meeting
  • Date: Friday, November 18, 2016
  • Time: 7:00 PM MST (5:00 PM ET)
  • Location: Scottsdale Fairmont Princess Hotel in Scottsdale, AZ
  • Event Website:

About VBI Vaccines

VBI Vaccines Inc. (“VBI”) is a commercial-stage biopharmaceutical company developing a next generation of vaccines to address unmet needs in infectious disease and immuno-oncology. VBI’s first marketed product is Sci-B-Vac®, a hepatitis B (“HBV”) vaccine that mimics all three viral surface antigens of the hepatitis B virus; Sci-B-Vac is approved for use in Israel and 14 other countries. VBI’s eVLP Platform technology allows for the development of enveloped (“e”) virus-like particle (“VLP”) vaccines that closely mimic the target virus to elicit a potent immune response. VBI is advancing a pipeline of eVLP vaccines, with lead programs in cytomegalovirus (“CMV”) and glioblastoma multiforme (“GBM”). VBI is also advancing its LPV™ Thermostability Platform, a proprietary formulation and process that allows vaccines and biologics to preserve stability, potency, and safety. VBI is headquartered in Cambridge, MA with research operations in Ottawa, Canada and research and manufacturing facilities in Rehovot, Israel.

VBI Company Contact

Perri Maduri, Communications Executive
Phone: (617) 830-3031 x124

VBI Investor Contact

Nell Beattie, Director, Corporate Development and Investor Relations
Phone: (617) 830-3031 x128

Forward-Looking Statement Disclosure

Certain statements in this news release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation (collectively, “forward-looking statements”) that may not be based on historical fact, but instead relate to future events, including without limitation statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect” and similar expressions. All statements other than statements of historical fact included in this release are forward-looking statements. Such forward-looking statements include, but are not limited to, summary content of the presentation, filing an IND application in the first half of 2017 and VBI-1901’s potential for clinical success.

Such forward-looking statements are based on a number of assumptions, including assumptions regarding the successful development and/or commercialization of the company’s products, including the receipt of necessary regulatory approvals; general economic conditions; competitive conditions; and changes in applicable laws, rules and regulations.

VBI cautions the reader that forward-looking statements and information involve known and unknown risks, uncertainties and other factors that may cause actual results and developments to differ materially from those expressed or implied by such forward-looking statements or information contained in this news release and VBI has made assumptions and estimates based on or related to many of these factors.

Given these risks, uncertainties and factors, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on the company’s current expectations, and the company undertakes no obligation to revise or update such forward-looking statements and information to reflect subsequent events or circumstances, except as required by law.